Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aripiprazole

FDA-approved product (tablet, oral), marketed as Abilify, Abilify Asimtufii, Abilify Maintena Kit and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Aripiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Agitation
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Depressive disorder
  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aripiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aripiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

    NCT03568500 · start 2018-05-21

    Registered record
    Registry ID
    NCT03568500
    Conditions
    Schizophrenia; Schizoaffective Disorder; First Episode Psychosis
    Interventions
    Digital Medicine System; Aripiprazole; Olanzapine; Quetiapine; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-21
    Completion
    2019-09-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; First Episode Psychosis
    InterventionDigital Medicine System; Aripiprazole; Olanzapine; Quetiapine +1 more
    PhasePhase 4
    Registry statusCompleted

  • CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

    NCT03408873 · start 2018-04-01

    Registered record
    Registry ID
    NCT03408873
    Conditions
    Bipolar Disorder; Medication Adherence; Medication Non Adherence
    Interventions
    Abilify Maintena; Customized Adherence Enhancement (CAE)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-04-01
    Completion
    2020-05-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Medication Adherence; Medication Non Adherence
    InterventionAbilify Maintena; Customized Adherence Enhancement (CAE)
    PhasePhase 4
    Registry statusCompleted

  • Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

    NCT03442101 · start 2018-04-01

    Registered record
    Registry ID
    NCT03442101
    Conditions
    Psychosis
    Interventions
    Patients with psychosis will be treated with known antipsychotic medication
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2018-04-01
    Completion
    2026-12-31
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis
    InterventionPatients with psychosis will be treated with known antipsychotic medication
    PhaseNot recorded
    Registry statusActive not recruiting

  • Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study

    NCT03289026 · start 2017-09-01

    Registered record
    Registry ID
    NCT03289026
    Conditions
    Acute Schizophrenia Episode
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2021-02-02
    Enrolment
    770

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Schizophrenia Episode
    InterventionAripiprazole
    PhasePhase 4
    Registry statusCompleted

  • Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

    NCT03198078 · start 2017-06-30

    Registered record
    Registry ID
    NCT03198078
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole (OPC-34712); Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-06-30
    Completion
    2023-04-03
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole (OPC-34712); Aripiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

    NCT02722967 · start 2016-03

    Registered record
    Registry ID
    NCT02722967
    Conditions
    Schizophrenia; Major Depressive Disorder; Bipolar I Disorder
    Interventions
    Aripiprazole + IEM (Ingestible Event Marker)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-09
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Major Depressive Disorder; Bipolar I Disorder
    InterventionAripiprazole + IEM (Ingestible Event Marker)
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients

    NCT02630888 · start 2014-08

    Registered record
    Registry ID
    NCT02630888
    Conditions
    Bipolar Disorder
    Interventions
    Memantine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-08
    Completion
    2020-09
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionMemantine; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

    NCT02091882 · start 2014-03-21

    Registered record
    Registry ID
    NCT02091882
    Conditions
    Device Latency
    Interventions
    Placebo; Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-03-21
    Completion
    2014-04-18
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDevice Latency
    InterventionPlacebo; Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
    PhasePhase 4
    Registry statusCompleted

  • Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

    NCT02046564 · start 2014-02

    Registered record
    Registry ID
    NCT02046564
    Conditions
    Major Depressive Disorder
    Interventions
    ASC-01; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2016-09
    Enrolment
    412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionASC-01; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

    NCT02054702 · start 2014-02

    Registered record
    Registry ID
    NCT02054702
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole; Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-07
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole; Aripiprazole
    PhasePhase 3
    Registry statusCompleted

  • 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

    NCT01844700 · start 2013-07

    Registered record
    Registry ID
    NCT01844700
    Conditions
    High Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    Interventions
    Ziprasidone; aripiprazole, quetiapine, or risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
    InterventionZiprasidone; aripiprazole, quetiapine, or risperidone
    PhasePhase 4
    Registry statusTerminated

  • Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

    NCT01696617 · start 2012-02-10

    Registered record
    Registry ID
    NCT01696617
    Conditions
    Major Depressive Disorder
    Interventions
    Aripiprazole 6-week group; Aripiprazole 8-week group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02-10
    Completion
    2019-02
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAripiprazole 6-week group; Aripiprazole 8-week group
    PhasePhase 4
    Registry statusCompleted

  • Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study

    NCT01520350 · start 2012-02

    Registered record
    Registry ID
    NCT01520350
    Conditions
    Bipolar Disorder; Depressive Episode
    Interventions
    Low dose Adjunctive Aripiprazole; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2013-06
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Depressive Episode
    InterventionLow dose Adjunctive Aripiprazole; placebo
    PhasePhase 3
    Registry statusTerminated

  • Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

    NCT01509053 · start 2012-01

    Registered record
    Registry ID
    NCT01509053
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole (Abilify®) IM Depot Injection; Oral aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2012-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole (Abilify®) IM Depot Injection; Oral aripiprazole
    PhasePhase 3
    Registry statusTerminated

  • Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

    NCT01418352 · start 2011-08-02

    Registered record
    Registry ID
    NCT01418352
    Conditions
    Tourette's Disorder
    Interventions
    Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08-02
    Completion
    2014-03-12
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette's Disorder
    InterventionAripiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted